Related Experiment Video
Updated: Jun 14, 2026
Tubal Cytology of the Fallopian Tube as a Promising Tool for Ovarian Cancer Early Detection
Published on: July 25, 2017
LyGDI is a promising biomarker for ovarian cancer
Hongying Zhen1, Shaomin Yang, Hounan Wu
1Department of Cell Biology, Peking University Health Science Center, Beijing, China.
Introduction:
LyGDI is an inhibitor of Rho protein activation by blocking its transformation between guanosine 5'-diphosphate- and guanosine 5'-triphosphate-bound states. The aim of this study was to investigate the usefulness of LyGDI as a biomarker for the detection of ovarian cancer, and its specificity and sensitivity were compared with those of cancer antigen 125 (CA125).
Methods:
The serum levels of LyGDI were determined by enzyme-linked immunosorbent assay in 42 patients with ovarian disease, including 30 ovarian cancers and 12 benign ovarian lesions, and 76 healthy controls. The expression of LyGDI was also evaluated by immunohistochemical staining in resected ovarian tissues of these patients.
Results:
The serum LyGDI level of cancers was significantly greater than those of the benign and healthy groups (P = 0.002 and P < 0.0001, respectively), whereas no difference was observed between the benign and control groups (P = 0.889). Based upon receiver operating characteristic curve analysis, LyGDI levels were able to distinguish ovarian cancer from benign ovarian disease (P = 0.0001) and healthy control (P < 0.0001; areas under the receiver operating characteristic curves, 0.876 and 0.833, respectively). For ovarian cancers, 83.3% (25/30) or 80.0% (24/30) was identified by serum LyGDI (> or = 1.5 ng/mL) alone or by CA125 (>35 U/mL) alone. It is of particular importance to note that all cancer patients were identified by use of both markers, and the specificity was 83.3% for the benign group. Moreover, in early-stage cancers, 88.9% (8/9) had elevated serum LyGDI levels as compared with 44.4% (4/9) elevation of CA125 levels (P = 0.125). Immunohistochemical staining confirmed the expression of LyGDI on cancerous epithelial cells other than benign ovarian epithelium.
Conclusions:
These results suggest that LyGDI has significant potential as a marker for detection of ovarian cancer in the patients with ovarian enlargement, including detection of early-stage cancers.
Insights
LyGDI shows promise as a biomarker for ovarian cancer detection. Elevated LyGDI levels accurately identified ovarian cancers, including early stages, outperforming CA125 in some cases.
Area of Science:
- Oncology
- Biochemistry
- Molecular Biology
Background:
- LyGDI inhibits Rho protein activation by blocking its guanine nucleotide exchange.
- Ovarian cancer diagnosis often relies on biomarkers with limited sensitivity and specificity.
Purpose of the Study:
- To evaluate LyGDI as a potential biomarker for ovarian cancer detection.
- To compare the diagnostic performance of LyGDI with cancer antigen 125 (CA125).
Main Methods:
- Serum LyGDI levels were measured using ELISA in 42 patients (30 ovarian cancer, 12 benign lesions) and 76 healthy controls.
- LyGDI expression was assessed in ovarian tissues via immunohistochemical staining.
Main Results:
- Serum LyGDI levels were significantly higher in ovarian cancer patients compared to benign and control groups (P < 0.0001).
- LyGDI demonstrated good diagnostic accuracy (AUC 0.876 vs. benign, 0.833 vs. control).
- Combined LyGDI and CA125 detected all ovarian cancer cases with 83.3% specificity for benign disease.
Conclusions:
- LyGDI shows significant potential as a biomarker for ovarian cancer detection, particularly in patients with ovarian enlargement.
- LyGDI may aid in the early detection of ovarian cancers, showing higher detection rates than CA125 in early stages.
